Skip to main content
Apply for Grants

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

  • ${value}

Filter Results (1956${count})

  • Therapeutic Pipeline Program, 2021
    Understand Me for Life: An Intelligibility App for Parkinson's Disease

    Study Rationale:
    Approximately 90% of people with Parkinson’s develop speech and language problems over the course of the disease, and more than half of these speakers experience problems with...

  • Research Grant, 2021
    Hypoxia (Lowering Oxygen Levels) as a Novel Treatment for Parkinson’s Disease

    Study Rationale:
    Many anecdotes suggest that people with Parkinson’s disease (PD) can experience a marked improvement in symptoms when they travel to the mountains or during flights at high altitude...

  • Target Advancement Program, 2021
    Modulation of Epigenetic Regulator HDAC4 as a Parkinson’s Treatment

    Study Rationale:
    Scientists can take skin cells from people with Parkinson’s disease (PD), turn them into stem cells, and then engineer them into dopamine neurons, the cell type lost in PD. Our...

  • Therapeutic Pipeline Program, 2021
    Dietary Interventions to Slow and Improve Parkinson’s Symptoms by Restructuring the Gut Microbiome and Decreasing Inflammation

    Study Rationale:
    There is a link between the gut and the brain in Parkinson’s disease (PD), and gut bacteria may play an important role. Gut bacteria they affect the bowel mucus barrier, produce...

  • Priority Biology, 2021
    LRRK2 Regulation of Melanoma Progression

    Study Rationale:
    People with Parkinson's disease (PD) are more likely to develop melanoma, and people with melanoma are more likely to develop PD than the general population. Additionally, melanoma...

  • Therapeutic Pipeline Program, 2021
    RNA Targeting Small Molecules as Therapeutics for Parkinson's

    Study Rationale:    
    Abnormal clumping of the protein alpha-synuclein is a hallmark of Parkinson's disease (PD) and a likely cause of neurodegeneration and, ultimately, symptoms. One of the causes...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.